Cash Flow Statement (Annual)

AMD / Advanced Micro Devices, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Net Income Loss - 471,000 491,000 -1,183,000 -83,000 -403,000 -660,000 -497,000 43,000
  Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation Depletion And Amortization - - - - 236,000 203,000 167,000 133,000 144,000
    Share Based Compensation 75,000 87,000 90,000 97,000 91,000 81,000 63,000 86,000 97,000
    Amortization Of Financing Costs And Discounts 121,000 30,000 21,000 23,000 25,000 17,000 11,000 21,000 36,000
    Gains Losses On Extinguishment Of Debt 169,000 -24,000 -6,000 0 -1,000 -61,000 0 -68,000 -12,000
    Other Noncash Income Expense 44,000 27,000 3,000 -7,000 1,000 13,000 3,000 6,000 -3,000
  Increase Decrease In Operating Capital
    Increase Decrease In Accounts Receivable 960,000 1,138,000 347,000 -290,000 200,000 -7,000 -280,000 -222,000 89,000
    Increase Decrease In Inventories -89,000 144,000 -157,000 83,000 322,000 -199,000 11,000 73,000 -12,000
    Increase Decrease In Due From Related Parties Current - - - - - - - - -
    Increase Decrease In Prepaid Deferred Expense And Other Assets - 97,000 -115,000 20,000 11,000 7,000 111,000 166,000 140,000
    Increase Decrease In Due To Related Parties Current - - - - - -146,000 27,000 10,000 -
    Increase Decrease In Accounts Payable And Accrued Liabilities -133,000 -182,000 -148,000 -232,000 266,000 -231,000 -156,000 58,000 -75,000
  Net Cash Provided By Used In Operating Activities 473,000 -412,000 382,000 -338,000 -148,000 -98,000 -226,000 90,000 68,000
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Property Plant And Equipment 466,000 148,000 250,000 133,000 84,000 95,000 96,000 77,000 113,000
  Payments To Acquire Available For Sale Securities Debt - - - - - - - - -
  Proceeds From Sale And Maturity Of Available For Sale Securities 603,000 1,640,000 1,726,000 1,348,000 1,344,000 873,000 462,000 0 222,000
  Payments For Proceeds From Other Investing Activities -4,000 -19,000 19,000 9,000 0 0 0 -2,000 2,000
  Net Cash Provided By Used In Investing Activities -1,273,000 -1,123,000 -113,000 -19,000 455,000 -12,000 147,000 267,000 -114,000
Net Cash Provided By Used In Financing Activities
  Proceeds From Short Term Debt - - - - - - - - -
  Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options - - - - - 4,000 5,000 20,000 20,000
  Repayments Of Long Term Debt - - - - - - - - -
  Proceeds From Payments For Other Financing Activities 1,000 4,000 -5,000 -2,000 -1,000 -6,000 -2,000 -4,000 -13,000
  Net Cash Provided By Used In Financing Activities 1,524,000 484,000 -6,000 37,000 13,000 46,000 59,000 122,000 -33,000
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect - - - - - - - - -
Supplemental Cash Flow Information
  Cash Flow Noncash Investing And Financing Activities Disclosure
    Capital Expenditures Incurred But Not Yet Paid - - - - - - 0 0 50,000
    Stock Issued1 - - - - - 0 0 8,000 38,000
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
  Cash And Cash Equivalents At Carrying Value - - 869,000 549,000 869,000 805,000 785,000 1,264,000 1,185,000
  Restricted Cash Current - - - - - - - - -
  Restricted Cash Noncurrent - - - - - - - - -
  Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - - - -

Peers - Semiconductors and Related Devices (3674)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 007903107